Navigation Links
PIP - A Revolution in Stress Management
Date:9/25/2007

The power to relax is at your fingertips

SAN DIEGO, Sept. 25 /PRNewswire/ -- DEMOfall 07 -- Vyro Games today showcased PIP -- Personal Input Pod(TM) -- a revolutionary biosensor that helps manage stress.

The PIP communicates wirelessly with software applications that run on Bluetooth(TM) enabled devices such as mobile phones, PCs, Macs, and game consoles. The PIP is part of a unique stress management solution. It is highly portable, and empowers individuals to help them take control of their stress in a fun and engaging way.

"A walk in the park during a stressful work day is a luxury that few people can afford," says Paul Kewene-Hite, CEO of Vyro Games. "The PIP and applications will be affordable and will work wherever you need it at a moment's notice. Managing stress is now literally in your hands, at your fingertips."

"Stress is a major health issue worldwide. Vyro Games and the PIP provide a high-performance personal relaxation solution in a tiny package," says Chris Shipley, executive producer of the DEMOfall conference, where the PIP debuted. "You've got stress, you need a PIP."

A technology platform

Vyro Games' technology platform is designed to help users hone their skills in the virtual world, so that they can apply those relaxation skills in every day life. Learning to control, moderate or even eliminate one's stress is a life improving skill. Vyro's games offer a fun and constructive way for people to learn how to manage stress by relaxing.

The PIP technology platform delivers real-time feedback via Bluetooth(TM) communication with a host device. A software application toolkit from Vyro Games will allow developers to create applications for healthcare, sports training and gaming.

Games with a twist

Games on a mobile phone and PC are the first applications to work with PIP technology. They are fun, engaging and appeal to everyone -- from CEOs to moms, and other casual and non-tradi
'/>"/>

SOURCE Vyro Games
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Hemopurifier may revolutionise AIDS treatment
2. Revolutionary Simple Pregnancy Blood Test Can Save Both Mother And Child
3. Revolution in Genetics to Open Avenues for Treating Cancer
4. Revolution in surgery
5. Percutaneous aortic valve replacement- a revolution in Cardiac Surgery
6. Nanotechnology Revolution To Be Spearheaded By European Union
7. Enhanced Gene Therapy Outcomes Following Latest Revolution And Refinement
8. Complete Robotic Surgery To Revolutionize Surgical Treatment of Prostate Cancer
9. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
10. Heart Stem Cells Could Revolutionize Cardiac Disease Therapy
11. Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ONTO, Jan. 8 /PRNewswire-FirstCall/ - Med-Emerg In... Canada,s leading providers of health services, is...ted in favour of the previously announced plan of ...oup Inc. ("AIM") at a special meeting of MedEmerg,... 90% of the votes cast at the meeting were in favo...
(Date:1/8/2009)...XANDRIA, Va., Jan. 8 To...nization along with several national leadership or... the principles of hospice care and protection of ...anding together in sharing this unified message ab...of Hospice and Palliative Medicine, Hospice and Pa...
(Date:1/8/2009)...ifornia Assembly Member Tom Torlakson Introduces A...-USNewswire/ -- Today, Lung Cancer Alliance-Cali... Tom Torlakson (D-11th District) for his continued...unding for lung cancer research. For the third co...ancer research is being considered in the Californ...
(Date:1/8/2009)...says it lowered bad cholesterol more effectively t...y News) -- After nearly a year of review, U.S. hea...e continued use of the controversial cholesterol-l...Administration said there was no significant diffe... taking Vytorin and patients taking the drug Zocor...
Breaking Medicine News(10 mins):Health News:Shareholders of Med-Emerg International Inc. approve plan of arrangement with AIM Health Group Inc. 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:FDA Backs Cholesterol Drug Vytorin 2
... walk and stick to healthy food. That is a far mor... a group of US scientists has said.// In fact pr...tified when lifestyle changes are just as effectiv...osiglitazone pills do work, but so does weight los...
...ch has shown a way for people suffering diabetic r...arding as well as alleviating the effects of diabe... consequence of diabetes. In the initial stages, ...le symptoms but is capable of progressing graduall...
... outcomes for blacks with cardiovascular disease a...ferences in access and treatment are minimized, ac...rt Journal, Reuters reports. For the study, Nanc...emorial Veterans Hospital and colleagues studied t...
...w of the massacre that took place last week at the...iversity officials are asking the congressmen to f...isaster. Some kind of program, to identify and tre... and the others. A law that would permit the unive...
Other Medicine News:Health News:Lifestyle changes not prescription drugs to fight diabetes, say scientists 2Health News:Measures Needed to Avert Another Bloodbath 2
(Date:1/8/2009)...ated at the initial dose in an ongoing Phase Ib tr...line after three days , , Conference Call Today...re-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nas...st cohort of an ongoing Phase Ib clinical trial of...ide polymerase inhibitor. ANA598 was very well-to...
(Date:1/7/2009)...n., Jan. 7 Scientists h...high likelihood of relapse in children with acute ...hers caution that further research is needed to de... IKAROS, lead to leukemia relapse, the findings ...tic tests to assess the risk of treatment failure....
(Date:1/7/2009)...d., Jan. 7 ImQuest Life Sciences a... application to the Food and Drug Administration t...rimidinedione HIV inhibitor IQP-0410. ImQuest anti...rst quarter of 2009. IQP-0410 is a novel small mol...onnucleoside reverse transcriptase inhibitor (NNRT...
(Date:1/7/2009).... 7 Tiantan Puhua Hospital Stem Ce...worldwide leader in using stem cells to effectivel...x new globally experienced additions to its medica... hospital,s treatment capabilities for growing num...enior doctors include the distinguished Dr. Jiang ...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Continuous Blood Pressure Monitoring Predicts Risks 30515 1Continuous Blood Pressure Monitoring Predicts Risks 30515 2Continuous Blood Pressure Monitoring Predicts Risks 30515 311 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 111 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 211 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 311 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 411 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 511 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 611 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 7Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition 30509 1Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition 30509 2Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment 30506 1Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment 30506 2
...3, 2007 - Affymax, Inc.,(Nasdaq:AFFY) today announ...ical trials of Hematide(TM) in dialysis and,non-di...data showed,that in treatment naive, non-dialysis ...stered monthly at an appropriate dose.,Similarly, ...ith,three-times weekly Epoetin Alfa demonstrated t...
...7 - CytRx Corporation,(NASDAQ:CYTR) today announce...logy exclusively licensed to its majority-owned,su...as been,published in the April 2007 issue of peer-...The technology was developed by RXi,Co-founder, Sc...assachusetts Medical School (UMMS) Professor of Bi...
Other Medicine Technology:Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 2Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches.
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches.
Curved shafts and tips with 6 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches.
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Straight shafts. Overall length 3.9 inches.
Medicine Products: